| olanzapine / Generic mfg. |
2006-005346-37: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental Disorders |
|
|
| | 3 | 576 | Europe | olanzapine, Tablet, Capsule*, ZYPREXA | Eli Lilly and Company Limited | children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD) | | | | |
ACTRN12621001238864p: PEAChY-M
Pharmacological Emergency management of Agitation in Children and Young people: a randomised controlled trial of intraMuscular medication |
|
|
| Not yet recruiting | 3 | 348 | | | Murdoch Children's Research Institute (MCRI), Medical Research Futures Fund Million Minds Mission administered through the Department of Health | acute severe behavioural disturbance | | | | |
ACTRN12621001238864: PEAChY-M
Pharmacological Emergency management of Agitation in Children and Young people: a randomised controlled trial of intraMuscular medication |
|
|
| Recruiting | 3 | 348 | | | Murdoch Children's Research Institute (MCRI), Medical Research Futures Fund Million Minds Mission administered through the Department of Health, Western Australia Child Research Fund, Emergency Medicine Foundation | acute severe behavioural disturbance | | | | |
NCT00065273: Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay |
|
|
| Completed | 3 | 50 | US | risperidone, clozapine, olanzapine | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Mental Retardation, Developmental Delay Disorder | | 06/01 | | |
NCT00236457: A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 629 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Psychotic Disorders | | 12/02 | | |
NCT00712686: Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia |
|
|
| Completed | 3 | 690 | Europe, RoW | Aripiprazole, Abilify, Olanzapine | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 12/03 | 12/03 | | |
NCT00159770: Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients |
|
|
| Completed | 3 | 290 | Europe, RoW | ziprasidone versus olanzapine , risperidone or quetiapine, Panss , CGI-C, UKU-SERS-Pa, Blood tests | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Schizophrenia, Schizoaffective Disorder, Psychotic Disorders | | 09/04 | | |
NCT00077714: Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia |
|
|
| Completed | 3 | 12 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 01/05 | | |
NCT00078039: Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 630 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 01/05 | | |
NCT00034892: CAFE Comparison of Atypicals in First Episode of Psychosis |
|
|
| Completed | 3 | | US, Canada | Olanzapine, risperidone | AstraZeneca, University of North Carolina | Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders | 03/05 | 03/05 | | |
NCT00051298: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia |
|
|
| Completed | 3 | 107 | US, RoW | Olanzapine, Placebo | Eli Lilly and Company | Schizophrenia | | 04/05 | | |
NCT00083668: Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 619 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 05/05 | | |
NCT00485680: Olanzapine Versus Comparator in the Treatment of Bipolar Disorder |
|
|
| Completed | 3 | 140 | RoW | Olanzapine Hydrochloride, Lithium Carbonate | Eli Lilly and Company | Bipolar Disorder | | 06/05 | | |
| Completed | 3 | 700 | Europe | Aripiprazole, Abilify, Olanzapine or Quetiapine or Risperidone | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka America Pharmaceutical | Schizophrenia | 08/05 | 08/05 | | |
NCT00145444: Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study |
|
|
| Completed | 3 | 100 | Europe | olanzapine, ziprasidone | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Schizophrenia, Psychotic Disorders | | 11/05 | | |
NCT00091650: Olanzapine in Patients With Borderline Personality Disorder |
|
|
| Completed | 3 | 300 | US, Europe | Olanzapine, placebo | Eli Lilly and Company | Borderline Personality Disorder | | 11/05 | | |
NCT00210769: A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia |
|
|
| Completed | 3 | 203 | US | paliperidone ER Oros | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 12/05 | | |
NCT00088036: Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder |
|
|
| Completed | 3 | 450 | US, Europe, RoW | Olanzapine | Eli Lilly and Company | Borderline Personality Disorder | | 01/06 | | |
NCT00230828: Patient-reported Outcomes in the Treatment of Schizophrenia |
|
|
| Completed | 3 | | US | bifeprunox | Solvay Pharmaceuticals | Schizophrenia | 01/06 | | | |
NCT00211562: Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids |
|
|
| Terminated | 3 | 20 | US | Olanzapine, Omega 3, Vitamin E+C | Augusta University, Eli Lilly and Company, Medical Service Line ABRC, US Department of Veterans Affairs | Schizophrenia | 01/06 | | | |
NCT00151424: Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947) |
|
|
| Completed | 3 | 277 | NA | asenapine, Placebo, Olanzapine | Organon and Co | Schizophrenia | 01/06 | 02/06 | | |
NCT00194064: Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine |
|
|
| Terminated | 3 | 18 | US | Olanzapine, Zyprexa | University Hospitals Cleveland Medical Center, Eli Lilly and Company | Bipolar Disorder | 02/06 | 02/06 | | |
NCT00650793: A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia |
|
|
| Completed | 3 | 473 | US | Extended Release OROS® Paliperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 02/06 | | |
NCT00113594: Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder |
|
|
| Completed | 3 | 100 | US, RoW | Olanzapine | Eli Lilly and Company | Schizophrenia, Bipolar Disorder | | 03/06 | | |
NCT00212784: Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) |
|
|
| Completed | 3 | 1225 | NA | asenapine, Org 5222, SCH 900274, olanzapine | Organon and Co | Schizophrenia, Schizoaffective Disorder | 03/06 | 03/06 | | |
NCT00159796: 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009) |
|
|
| Completed | 3 | 489 | NA | Asenapine, Org 5222, Olanzapine, Placebo | Organon and Co, Pfizer | Bipolar Disorder | 03/06 | 04/06 | | |
NCT00156117: Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933) |
|
|
| Completed | 3 | 417 | NA | asenapine, Placebo, olanzapine | Organon and Co | Schizophrenia | 04/06 | 05/06 | | |
NCT00159744: 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008) |
|
|
| Completed | 3 | 488 | NA | Asenapine, Org 5222, Olanzapine, Placebo | Organon and Co, Pfizer | Bipolar Disorder | 04/06 | 04/06 | | |
NCT00143182: 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED) |
|
|
| Completed | 3 | 504 | NA | Asenapine, Org 5222, Olanzapine | Organon and Co, Pfizer | Bipolar Disorder | 06/06 | 06/06 | | |
NCT00095524: Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 300 | US, Europe, RoW | Aripiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka America Pharmaceutical | Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder | 08/06 | 08/06 | | |
| Completed | 3 | 440 | NA | asenapine, Org 5222, SCH 900274, olanzapine, Zyprexa | Organon and Co | Schizophrenia, Schizoaffective Disorder | 09/06 | 10/06 | | |
| Completed | 3 | | US | bifeprunox | Solvay Pharmaceuticals | Schizophrenia | 11/06 | 11/06 | | |
NCT00159783: 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857) |
|
|
| Completed | 3 | 218 | NA | asenapine, Org 5222, Olanzapine | Organon and Co, Pfizer | Bipolar Disorder | 04/07 | 04/07 | | |
NCT00156091: Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784) |
|
|
| Completed | 3 | 260 | NA | Olanzapine, Asenapine, Placebo | Organon and Co | Schizophrenia | 06/07 | 06/07 | | |
NCT00212836: Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817) |
|
|
| Completed | 3 | 481 | NA | asenapine, olanzapine, Zyprexa | Organon and Co | Schizophrenia | 06/07 | 08/07 | | |
2004-002560-17: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia |
|
|
| Completed | 3 | 444 | Europe, RoW | Asenapine tablets, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Org 5222, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Tablet, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets | NV Organon, Pfizer Limited, ORGANON ITALIA | Schizophrenia with predominant, persistent negative symptoms | | | | |
NCT00350467: A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia |
|
|
| Completed | 3 | 288 | RoW | ER OROS paliperidone and Olanzapine | Xian-Janssen Pharmaceutical Ltd. | Acute Schizophrenia | | 09/07 | | |
NCT00380224: Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia. |
|
|
| Completed | 3 | 120 | US | bifeprunox, olanzapine | Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia | | 09/07 | | |
NCT00396565: A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia |
|
|
| Completed | 3 | 394 | Japan | ER OROS paliperidone, Placebo, Olanzapine | Janssen Pharmaceutical K.K. | Schizophrenia | 11/07 | 11/07 | | |
NCT00265343: 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777) |
|
|
| Completed | 3 | 306 | NA | asenapine, olanzapine | Organon and Co | Schizophrenia | 12/07 | 01/08 | | |
| Withdrawn | 3 | 30 | Europe | Olanzapine, EU/1/96/022/002+019 | Charite University, Berlin, Germany, Eli Lilly and Company | Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression | 01/08 | 04/08 | | |
2005-002169-35: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543 |
|
|
| Completed | 3 | 380 | Europe, RoW | Asenapine tablets, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Org 5222, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Tablet, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets | NV Organon, Pfizer Limited, ORGANON ITALIA, PFIZER | Schizophrenia with predominant, persistent negative symptoms | | | | |
| Completed | 3 | 286 | US, Canada, Europe, RoW | Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone | Solvay Pharmaceuticals, H. Lundbeck A/S, Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia and Schizoaffective Disorder | 02/08 | 02/08 | | |
| Completed | 3 | 50 | US | Injectable Risperidone (Consta) or oral antipsychotic, Long actiing risperidone injection (Consta), oral risperidone (risperdal)., Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify) | University of Pittsburgh, Janssen Pharmaceuticals | Bipolar I Disorder | 03/08 | 12/09 | | |
NCT00759421: Exploratory Cognition Study of Sertindole in Patients With Schizophrenia |
|
|
| Completed | 3 | 96 | RoW | Sertindole, Olanzapine, Zyprexa | H. Lundbeck A/S | Schizophrenia | 03/08 | 04/08 | | |
NCT00759460: Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia |
|
|
| Completed | 3 | 250 | RoW | Sertindole, Olanzapine, Zyprexa | H. Lundbeck A/S | Schizophrenia | 03/08 | 04/08 | | |
NCT00864045: Sertindole in Asian Patients With Schizophrenia |
|
|
| Completed | 3 | 394 | RoW | Sertindole, Olanzapine | H. Lundbeck A/S | Schizophrenia | 03/08 | 05/08 | | |
NCT00259272: Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine |
|
|
| Completed | 3 | 141 | Europe | olanzapine, LY170053, Velotab, Zydis | Eli Lilly and Company | Bipolar Disorder I or II | 05/08 | 05/08 | | |
| Completed | 3 | 259 | US, Canada | Olanzapine, Zyprexa, Sertraline, Zoloft, placebo | Weill Medical College of Cornell University, National Institute of Mental Health (NIMH) | Major Depressive Disorder With Psychotic Features | 06/08 | 06/08 | | |
NCT00124930: Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer |
|
|
| Terminated | 3 | 80 | Canada | Olanzapine, Haldol | Alberta Health services, Canadian Institutes of Health Research (CIHR) | Nausea, Neoplasms | 06/08 | 06/08 | | |
NCT00401973: Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine |
|
|
| Completed | 3 | 199 | US, RoW | olanzapine, LY170053, Zyprexa, amantadine, metformin, zonisamide, Wellness education | Eli Lilly and Company | Schizophrenia, Schizoaffective Disorders | 09/08 | 09/08 | | |
NCT00145496: Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771) |
|
|
| Completed | 3 | 468 | NA | Asenapine, Olanzapine | Organon and Co | Schizophrenia | 11/08 | 12/08 | | |
NCT00129220: Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder |
|
|
| Completed | 3 | 224 | Japan | olanzapine, LY170053, Zyprexa, haloperidol, placebo | Eli Lilly and Company | Bipolar Disorder | 01/09 | 01/09 | | |
NCT00438776: Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling |
|
|
| Completed | 3 | 42 | US | olanzapine, zyprexa, sugar pill, fake pill | Lindner Center of HOPE, Eli Lilly and Company, University of Cincinnati | Pathological Gambling | 03/09 | 03/09 | | |
NCT00174265: 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772) |
|
|
| Completed | 3 | 196 | NA | asenapine, olanzapine, Zyprexa | Organon and Co | Schizophrenia | 04/09 | 05/09 | | |
NCT00266630: Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder |
|
|
| Completed | 3 | 139 | Japan | olanzapine, LY170053, Zyprexa, lithium, valproate, carbamazepine | Eli Lilly and Company | Manic or Mixed Episode Associated With Bipolar I Disorder | 05/09 | 05/09 | | |
NCT00273624: Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial |
|
|
| Withdrawn | 3 | 0 | Europe | Olanzapine, Zyprexa, Placebo | University Hospital Freiburg | Therapy-resistant Depression | 12/09 | 12/09 | | |
| Completed | 3 | 478 | US, Europe, RoW | Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets | Sunovion | Schizophrenia | 12/09 | 01/10 | | |
|
NCT00510146: Olanzapine Treatment of Patients With Bipolar I Disorder |
|
|
| Completed | 3 | 514 | Japan, RoW | Olanzapine, LY170053, Zyprexa, Placebo | Eli Lilly and Company | Depression, Bipolar | 03/10 | 07/10 | | |
NCT00490971: A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder |
|
|
| Completed | 3 | 768 | US, Europe, RoW | Olanzapine, Paliperidone ER, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | 04/10 | 04/10 | | |
NCT00746785: A New Pharmacotherapy for Alcohol Dependence: Olanzapine |
|
|
| Completed | 3 | 304 | US | 2.5 mg Olanzapine, 5mg Olanzapine, placebo | The Mind Research Network | Alcohol Dependence | 05/10 | 09/11 | | |
NCT00149734: Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia |
|
|
| Completed | 3 | 8 | US | Ondansetron followed by placebo, Zofran, Zuplenz, Placebo followed by Ondansetron | University of Colorado, Denver, National Institute of Mental Health (NIMH) | Schizophrenia | 05/10 | 05/10 | | |
NCT00618748: Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed |
|
|
| Completed | 3 | 101 | Japan | Olanzapine, LY170053 | Eli Lilly and Company | Bipolar I Disorder | 09/10 | 09/10 | | |
NCT00363376: A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain |
|
|
| Completed | 3 | 42 | US | zonisamide, Zonegran, olanzapine, Zyprexa, Zydis, Zonisamide, Sugar Pill (placebo) | Lindner Center of HOPE, Eli Lilly and Company, University of Cincinnati | Weight Gain | 02/11 | 02/11 | | |
NCT01977300: Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode |
|
|
| Completed | 3 | 159 | Canada | Valproate, Valproic Acid, Lithium, Lithium Carbonate, Risperidone, Risperdal, Olanzapine, Zyprexa, Placebo, Sugar Pill | University of British Columbia, Canadian Institutes of Health Research (CIHR), Eli Lilly and Company, Janssen-Ortho Inc., Canada | Bipolar I Disorder | 08/11 | 08/11 | | |
| Withdrawn | 3 | 0 | US | Olanzapine (Zyprexa), Typicals | VA Connecticut Healthcare System, Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital, Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder | 06/12 | 06/12 | | |
NCT01184443: Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents |
|
|
| Terminated | 3 | 38 | Canada | Olanzapine, Teva-Olanzapine, Dins: 02276712 and 02276720 | Children's Hospital of Eastern Ontario | Eating Disorder | 08/13 | 03/14 | | |
NCT01617187 / 2010-018407-28: A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688) |
|
|
| Completed | 3 | 360 | NA | Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine | Organon and Co | Schizophrenia | 08/14 | 09/14 | | |
O2, ChiCTR-TTRCC-14004093: Olanzapine versus aprepitant for the prevention of high dose cisplatin -induced nausea and vomiting: a randomized phase III trial. |
|
|
| Completed | 3 | 320 | | Olanzapine | The Xiangya 2nd hospital Central South University; Level of the institution：, Jiangsu Haosen pharmaceutical Limited by Share Ltd | Vomiting | | | | |
| Completed | 3 | 105 | US | Asenapine, Saphris®, SCH 900274, Org 5222, Sycrest®, Placebo Asenapine, Olanzapine, Zyprexa, Placebo Olanzapine | Forest Laboratories | Schizophrenia | 03/15 | 03/15 | | |
NCT02116530: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy |
|
|
| Completed | 3 | 401 | US | Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | 04/15 | 11/15 | | |
CINV, ChiCTR-IPR-14005265: Comparison of the effects of Palonosetron and Dexamethasone with and without Olanzapine to prevent the nausea and vomiting induced by 3-day cisplatin based chemotherapy in cancer patients: a multi cen |
|
|
| Recruiting | 3 | 178 | | Olanzapine + Palonosetron + Dexamethsone ;Palonositron | the Fourth Affiliated Hospital of China Medical University; the Fourth Affiliated Hospital of China Medical Un, self - provided | malignant neoplasm | | | | |
NCT01765829 / 2011-004826-87: Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis |
|
|
| Unknown status | 3 | 104 | Europe | Discontinuation antipsychotic treatment, Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone, Antipsychotic treatment, Antipsychotic drugs | Fundación Pública Andaluza Progreso y Salud, Instituto de Salud Carlos III | Psychosis Nos/Other | 11/15 | 11/15 | | |
2006-000846-38: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder |
|
|
| Completed | 3 | 20 | Europe | Overencapsulated olanzapine 10mg, Overencapsulated olanzapine 5mg, paliperidone 3 mg overencapsulated tablets, paliperidone 6mg overencapsulated tablet, F292, F318, F022, F061, Zyprexa 5mg Filmtablette, Zyprexa 5 mg Filmtablette, Zyprexa 5mg Filmtablette, Zyprexa 5 mg Filmtablette | Janssen-Cilag International N.V. | Bipolar I disorder, most recent maniac or mixed episode | | | | |
2006-001490-15: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for theprevention of mood episodes in the treatment of subjects with bipolar I disorder |
|
|
| Completed | 3 | 32 | Europe | Risperdal 1 mg, Risperdal Consta/25 mg, Olanzapine, Risperdal Consta/37,5 mg, Risperdal Consta/50 mg, F005, F109, F292, Risperdal, Risperdal CONSTA, Zyprexa, Risperdal, Risperdal CONSTA, Zyprexa | Janssen-Cilag International N.V | Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and CGI-S | | 04/09 | | |
2006-006967-22: A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects with Schizophrenia |
|
|
| | 3 | 75 | Europe | paliperidone 3 mg, paliperidone 6 mg, OLANZAPINE 5 MG, OLANZAPINE 10 MG, f039, f040, INVEGA 3 mg prolonged-release tablets, INVEGA 6 mg prolonged release tablets, ZYPREXA, INVEGA 3 mg prolonged-release tablets, INVEGA 6 mg prolonged release tablets, ZYPREXA | Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium, Janssen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium, JANSSEN CILAG INTERNATIONAL NV | Subjects 18 – 65 years of age, who meets the DSM-IV criteria for schizophrenia with a PANSS total score at screening of 60-100 inclusive, and who in the opinion of the investigator will benefit from a treatment with paliperidone ER or olanzapine | | 04/09 | | |
2007-001520-12: Efficacy and distinctive effects of atypical antipsychotics on cognitive symptoms in dual diagnosis – A phase IIIb, randomized, open-labelled study to evaluate the cognitive effects of quetiapine XR and olanzapine in patients with schizophrenia and substance abuse |
|
|
| | 3 | 40 | Europe | Seroquel (sustained release formulation), Zyprexa, Zyprexa Velotab, Zyprexa Velotab | Unidade de Investigação em Saúde Mental e Psiquiatria do Centro Hospitalar Conde de Ferreira | Patients with both schizophrenia and substance abuse disorder | | 12/08 | | |
2008-000243-33: Alzheimer disease and antipsycotics: a long term multicenter randomized clinical trial |
|
|
| | 3 | 1000 | Europe | Risperidone, Olanzapine, Quetiapine, Haloperidol, | ISTITUTO SUPERIORE DI SANITA\' | BPSD in Alzheimer disease | | | | |
2008-005019-16: Randomized Olanzapine Clozapine Key study on Schizophrenia and Addiction in the Netherlands (ROCKSAN) |
|
|
| Ongoing | 3 | 140 | Europe | Olanzapine, clozapine, | AMC- academisch psychiatrisch centrum | A multi-centre prospective, randomized, double blind designed study examining the effectiveness and costs of clozapine compared to olanzapine in patients with schizophrenia or related psychotic disorders and co-morbid SUD. Study setting: in and out patients. Study duration: 6 months. | | | | |
| | 3 | 14 | Europe | Pomaglumetad methionil, ABILIFY, ZYPREXA, RISPERDAL, SEROQUEL, LY2140023, 129722-12-9, | Eli Lilly and Company, Lilly S.A., Eli Lilly and Company, , Lilly S.A. | Schizophrenia | | 08/12 | | |
AOPDPCINV, NCT02484911: Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting |
|
|
| Completed | 3 | 120 | RoW | Olanzapine, Aprepitant, Palonosetron, Dexamethasone | First Affiliated Hospital of Harbin Medical University, Harbin Medical University | Chemotherapy-induced Nausea and Vomiting | 09/16 | 01/17 | | |
2014-003834-21: Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial. Effectiviteit van penfluridol (oraal lang-werkend neurolepticum) in vergelijking met orale tweede-generatie antispychotica in patienten met een psychotische stoornis: een open label randomized controlled trial. |
|
|
| Terminated | 3 | 180 | Europe | olanzapine, risperdal, penfluridol, Coated tablet, Tablet, Zyprexa, risperidon | Erasmus Medical Center Rotterdam, ZonMw | Psychotic disorders Psychotische stoornissen, Psychotic disorder Psychotische stoornissen, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2013-004881-33: Multicentre trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescents Groß an gelegte, einfache offene klinische Studie mit mehreren teilnehmenden Prüfzentren zur Anwendung von Antidepressiva und Neuroleptika (mit /ohne Zulassung) |
|
|
| Ongoing | 3 | 1000 | Europe | Tablet, Abilify, Zyprexa, Leponex, Seroquel, Risperdal, Zeldox, Melneurin, Dipiperon, Saroten, Cipramil, Anafranil, Aponal, Cymbalta, Cipralex, Fluctin, Fevarin, Tofranil, Ludiomil, Remergil, Nortrilen, Paroxat, Zoloft, Stangyl, Trevilor | Universitätsklinikum Würzburg, Kompetenznetz TDM-KJP e.V., BfArM | therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, therapeutic use in clinical practise Therapeutische Anwendung im klinischen Alltag, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NEUROHD, NCT00632645: Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride |
|
|
| Completed | 3 | 180 | Europe | Olanzapine, Olanzapine Mylan, Xenazine, tetrabenazine, Tiapridal, tiapride | Assistance Publique - Hôpitaux de Paris | Huntington Disease | 04/17 | 04/17 | | |
NCT02374567: Pharmacovigilance in Gerontopsychiatric Patients |
|
|
| Terminated | 3 | 407 | Europe | Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine, Valproic Acid, Lamotrigine, Topiramate, Gabapentin, Levetiracetam, Pregabalin, Lacosamide, Clonazepam, Biperiden, Levomepromazine, Fluphenazine, Perphenazine, Perazine, Thioridazine, Haloperidol, Melperone, Pipamperone, Bromperidol, Benperidol, Sertindole, Ziprasidone, Flupentixol, Chlorprothixene, Zuclopenthixol, Fluspirilene, Pimozide, Clozapine, Olanzapine, Quetiapine, Sulpiride, Tiapride, Amisulpride, Prothipendyl, Risperidone, Aripiprazole, Paliperidone, Diazepam, Oxazepam, Lorazepam, Bromazepam, Clobazam, Alprazolam, Hydroxyzine, Buspirone, Chloral Hydrate, Flurazepam, Nitrazepam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Zopiclone, Zolpidem, Zaleplon, Melatonin, Clomethiazole, Diphenhydramine, Promethazine, Imipramine, Clomipramine, Opipramol, Trimipramine, Amitriptyline, Nortriptyline, Doxepin, Maprotiline, Amitriptyline oxide, Fluoxetine, Citalopram, Paroxetine, Sertraline, Fluvoxamine, Escitalopram, Tranylcypromine, Moclobemide, Mianserin, Trazodone, Mirtazapine, Bupropion, Venlafaxine, Reboxetine, Duloxetine, Agomelatine, Pyritinol, Piracetam, Donepezil, Rivastigmine, Galantamine, Memantine, Nicergoline, Acamprosate, Lithium | Hannover Medical School | Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders | 06/17 | 06/17 | | |
FOND-O, NCT02635984: Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens |
|
|
| Completed | 3 | 108 | US | Olanzapine, Zyprexa, Placebo | Augusta University, University of Georgia | Complications of Bone Marrow Transplant, Hematologic Neoplasms | 12/17 | 12/17 | | |
| Completed | 3 | 1098 | Europe, Canada, US, RoW | Risperidone, Olanzapine, Lu AF35700 | H. Lundbeck A/S | Schizophrenia | 08/18 | 10/18 | | |
2018-001514-15: Effects of early clozapine treatment on remission rates in acute schizophrenia (EARLY) Effekte der frühzeitigen Applikation von Clozapin auf die Remissionsrate bei akuter Schizophrenie |
|
|
| Not yet recruiting | 3 | 220 | Europe | Clozapin 1A-Pharma, Zyprexa Lilly, Capsule, hard | Bezirkskliniken Schwaben, DFG Grant Number HA 6091/4-1, project number: 316096538 | Schizophrenia Schizophrenie, Schizophrenia Schizophrenie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Terminated | 3 | 119 | Europe, Japan, US, RoW | Lu AF35700, Risperidone, Olanzapine | H. Lundbeck A/S | Treatment-resistant Schizophrenia | 12/18 | 02/19 | | |
NCT03219710: "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)" |
|
|
| Completed | 3 | 240 | RoW | Ondansetron, Dexamethasone, Aprepitant, Olanzapine | All India Institute of Medical Sciences, New Delhi | Chemotherapy-induced Nausea and Vomiting | 07/19 | 07/19 | | |
DREaM, NCT02431702: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform |
|
|
| Completed | 3 | 337 | US, RoW | Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M) | Janssen Scientific Affairs, LLC | Schizophrenia, Psychotic Disorders | 11/19 | 11/19 | | |
NCT02861859: Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study |
|
|
| Completed | 3 | 221 | Canada | Olanzapine, Mylan-Olanzapine, Olanzapine Placebo | Ottawa Hospital Research Institute | Breast Cancer | 12/19 | 12/19 | | |
| Completed | 3 | 30 | Canada | Zyprexa® (OLANZapine 5MG), Zyprexa®, Emend® (Aprepitant), Emend® | CR-CSSS Champlain-Charles-Le Moyne | Chemotherapy-induced Nausea and Vomiting | 12/19 | 12/19 | | |
NCT03876938: Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy |
|
|
| Unknown status | 3 | 147 | RoW | aprepitant, olanzapine 10 mg, olanzapine 5 mg | Mahidol University | Antiemetic for Highly Emetogenic Chemotherapy | 08/20 | 12/20 | | |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
NCT03079219: Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients |
|
|
| Completed | 3 | 120 | RoW | Experimental drug: Aprepitant, Experimental drug: Ondansetron, Experimental drug: Dexamethasone, Experimental drug: Olanzapine, Standard: Aprepitant, Standard: Ondansetron, Standard: Dexamethasone | CCTU | Breast Cancer | 03/21 | 03/21 | | |
| Completed | 3 | 90 | RoW | Olanzapine 10 Mg ORAL TABLET, Olanzapine 5 Mg ORAL TABLET, Placebo ORAL TABLET | Rajavithi Hospital | Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis | 06/21 | 09/21 | | |
A221602, NCT03578081: Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy |
|
|
| Completed | 3 | 690 | US, RoW | Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Malignant Neoplasm | 11/21 | 05/23 | | |
NCT03187769 / 2017-000497-11: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder |
|
|
| Completed | 3 | 426 | Europe, US, RoW | ALKS 3831, Olanzapine | Alkermes, Inc. | Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder | 12/21 | 01/22 | | |
|
NCT02939287: Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan |
|
|
| Completed | 3 | 52 | US | o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1, Emend, Olanzapine10 mg orally daily on Days -1,0,+1 and +2, Zyprexa, Aprepitant plus Olanzapine | Rush University Medical Center | Nausea, Vomiting | 12/21 | 12/22 | | |
